{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:32:10Z","timestamp":1791149530711,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Objectives: There are many explanations for increased levels of serum uric acid (SUA) in patients with psoriatic arthritis (PsA), but correlation with different treatment options in PsA is not well elucidated. Our aim was to determine the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on SUA levels in patients with PsA. Materials and methods: We analyzed the data of PsA patients treated with different bDMARDs from January 2007 to June 2021. Patients treated with interleukin-17 (IL-17) inhibitors (secukinumab and ixekizumab) and tumor necrosis factor \u03b1 (TNF\u03b1) inhibitors (golimumab, infliximab, adalimumab, certolizumab pegol, and etanercept) were included. Results: A total of 87 patients were included. The SUA levels decreased in 60 (69%) patients after a 3\u20136-month-long follow-up, and in 25 (28.7%), we noticed an increase. The average decrease in SUA levels was 9.4 \u00b1 49.5 \u00b5mol\/L (p = 0.039); for TNF\u03b1 patients, it was 7.3 \u00b1 59.8 \u00b5mol\/L (p = 0.386), and for IL-17 patients, it was 12.6 \u00b1 28.4 \u00b5mol\/L (p = 0.013). The levels of SUA decreased in 81.8% of patients treated with infliximab, as well as in 76% of those treated with secukinumab and in 72.7% of those treated with etanercept. The largest average decrease in SUA levels was recorded in the group treated with golimumab (23 \u00b5mol\/L). Conclusions: A significant decrease in SUA levels was noticed, especially in patients treated with IL-17 inhibitors. Further studies should identify which bDMARD is the most potent in the lowering of SUA levels. bDMARDs were efficient in PsA disease activity.<\/jats:p>","DOI":"10.3390\/cimb47030142","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:36:47Z","timestamp":1740375407000},"page":"142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis"],"prefix":"10.3390","volume":"47","author":[{"given":"Dijana","family":"Perkovi\u0107","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia"},{"name":"Department of Internal Medicine, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-9633","authenticated-orcid":false,"given":"Marin","family":"Petri\u0107","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Male\u0161","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Erceg Male\u0161","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-6800","authenticated-orcid":false,"given":"Mislav","family":"Radi\u0107","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital of Split, 21000 Split, Croatia"},{"name":"Department of Internal Medicine, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: Review and update","volume":"214","author":"Merola","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and managing comorbidities in psoriatic arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3899\/jrheum.170384","article-title":"Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia","volume":"45","author":"AlJohani","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00124743-200002000-00001","article-title":"Hyperuricemia in psoriatic arthritis: Prevalence and associated features","volume":"6","author":"Bruce","year":"2000","journal-title":"J. Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbrc.2018.02.166","article-title":"Serum levels of IL-17 are elevated in patients with acute gouty arthritis","volume":"497","author":"Liu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"104351","DOI":"10.1016\/j.phrs.2019.104351","article-title":"IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation","volume":"147","author":"Raucci","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tripolino, C., Ciaffi, J., Ruscitti, P., Giacomelli, R., Meliconi, R., and Ursini, F. (2021). Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications. Front. Med., 8.","DOI":"10.3389\/fmed.2021.737573"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rahimi-Sakak, F., Maroofi, M., Rahmani, J., Bellissimo, N., and Hekmatdoost, A. (2019). Serum uric acid and risk of cardiovascular mortality: A systematic review and dose-response meta-analysis of cohort studies of over a million participants. BMC Cardiovasc. Disord., 19.","DOI":"10.1186\/s12872-019-1215-z"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40292-020-00368-z","article-title":"Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project","volume":"27","author":"Maloberti","year":"2020","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_10","first-page":"CD008652","article-title":"Pharmacotherapy for hyperuricaemia in hypertensive patients","volume":"9","author":"Gois","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_13","first-page":"508","article-title":"Biological DMARD efficacy in psoriatic arthritis: A systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes","volume":"38","author":"Simons","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jacl.2022.09.006","article-title":"A mechanism-based operational definition and classification of hypercholesterolemia","volume":"16","author":"Civeira","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3122\/jabfm.19.3.310","article-title":"Hypertriglyceridemia","volume":"19","author":"Pejic","year":"2006","journal-title":"J. Am. Board Fam. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/1346-8138.13968","article-title":"Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients","volume":"44","author":"Tsuruta","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/15353702221110666","article-title":"Acute joint swelling in psoriatic arthritis: Flare or \u201cpsout\u201d-A 10-year-monocentric study on synovial fluid","volume":"247","author":"Galozzi","year":"2022","journal-title":"Exp. Biol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-4165(98)00028-2","article-title":"Xanthine oxidoreductase in human mammary epithelial cells: Activation in response to inflammatory cytokines","volume":"1381","author":"Page","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/CM9.0000000000002130","article-title":"Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hagino, T., Saeki, H., Fujimoto, E., and Kanda, N. (2023). Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051934"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00296-019-04394-6","article-title":"Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors","volume":"39","author":"Hasikova","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.18621\/eurj.359504","article-title":"Association between serum uric acid and inflammation markers in ankylosing spondylitis patients treated with tumor necrosis factor-\u03b1 or nonsteroidal anti-inflammatory drugs","volume":"5","year":"2019","journal-title":"Eur. Res. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e3676","DOI":"10.1097\/MD.0000000000003676","article-title":"Association of Serum Uric Acid Levels in Psoriasis: A Systematic Review and Meta-Analysis","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hu, M., Wang, Y., Xu, W., Bai, J., and Tang, X. (2024). The impact of serum uric acid on psoriasis: NHANES 2005-2014 and Mendelian randomization. Front. Genet., 9.","DOI":"10.3389\/fgene.2024.1334781"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhao, D., Zhao, J.R., Wang, S., and Sun, J.H. (2024). Evaluating causal influence of serum uric acid on psoriasis via observational study and transethnic Mendelian randomization analyses. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-77222-y"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and Psoriatic Arthritis: A Narrative Review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.02.050","article-title":"The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus phototherapy: An observational cohort study","volume":"79","author":"Wu","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajh.2012.12","article-title":"Effect of 1-year anti-TNF-\u03b1 therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: A controlled study","volume":"25","author":"Angel","year":"2012","journal-title":"Am. J. Hypertens."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1139\/cjpp-2015-0490","article-title":"Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance","volume":"94","author":"Liu","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/3\/142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:40:25Z","timestamp":1760028025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/3\/142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cimb47030142"],"URL":"https:\/\/doi.org\/10.3390\/cimb47030142","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]}}}